NCT00304655已完成4 期
Multicenter, Single Group Study of Aripiprazole Efficacy and Safety in the Acute Psychosis Treatment of Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder.
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 300
- 试验地点
- 2
- 主要终点
- PANSS-total score (at screening, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52)
研究概览
简要总结
The purpose of this study is to prove safety and efficacy of aripiprazole.
详细描述
This study was designed to prove safety and efficacy of aripiprazole in the treatment of acutely relapsed patients with diagnoses of schizophrenia or schizoaffective disorder in Korea and to confirm the maintenance of efficacy and safety during maintenance period and the changes in emotional factors and social functions.
After administering 15 mg/day of aripiprazole for two weeks, the test may change the dose within the range of 10 mg and 30 mg per day by clinical judgment. (Medication duration: 8 weeks (acute phase) + 18 weeks (maintenance phase)] + 26 weeks (extension phase), *total 52 weeks)
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Schizophrenia or schizoaffective disorder patients as defined by the DSM-IV criteria having an acute relapse
- •18 to 65 years
- •Males and females (females of child bearing potential must use acceptable contraception and must not be pregnant and lactating; females of child-bearing potential must have negative serum pregnancy test)
- •Randomization to this study must occur no more than four weeks following the day of initiation of treatment for the present episode/relapse.
- •Should have a total PANSS score of at least
- •In addition, patients should have scores of at least 4 ("moderate") on any two of the four PANSS items that constitute the psychotic item subscale (hallucinatory behavior, delusions, conceptual disorganization, and suspiciousness).
- •Patients must be able to be rated reliably on the battery of psychiatric and movement rating scales required by the protocol.
- •Patients eligible to enter the study must sign an informed consent form.
排除标准
- •Patients who are violent
- •Patients who, in the opinion of the investigator, have serious suicidal ideation
- •Patients who are liable to serious suicide attempt, by clinical judgment
- •Patients who currently have a psychiatric diagnosis other than schizophrenia, schizophrenic form disorder or schizoaffective disorder requiring pharmacotherapy
- •Patients who have any of the following neurologic diagnoses: migraine, epilepsy, Parkinson's disease, Alzheimer's disease, multiple sclerosis, residual of stroke, transient cerebral ischemic attacks, "cerebral palsy" or any other condition that requires intermittent or maintenance treatment, or which is manifested by any abnormality on neurologic examination
- •Patients who must continue to take, or who may potentially need to take, during this study, any of the following concomitant medication, which could cause unwanted drug-to-drug interactions or which could confound the analysis of antipsychotic effectiveness: Tegretol (carbamazepine), Depakene Depakote (valproic acid or sodium valproate or divalproate sodium), Lithium carbonate and lithium citrate
- •Patients under treatment of schizophrenia : those who had taken antipsychotic drugs (consta) before randomization
- •Patients who must continue to take, during this study, drugs or substances known as strong suppressive agents of microsomal enzyme CYP2D6
- •Patients with any gastrointestinal resection, stomach stapling, or any other condition that may impair the absorption of the study medication
- •Patients who currently meet the DSM-IV criteria for psychoactive substance dependence or patients with a history of substance or alcohol dependence (according to the DSM-IV criteria) within one month prior to the beginning of the study
- •Patients having any somatic condition whose symptoms or physical signs could be misinterpreted as signs or symptoms of psychosis or as adverse effects from antipsychotic medications.
- •Patients with any acute or unstable medical condition requiring pharmacotherapy
- •Patients with any abnormal laboratory test result as judged by investigator
- •Patients who have participated in any previous aripiprazole clinical study
- •Patients having taken an investigational drug within the four weeks which precede the start of placebo washout
结局指标
主要结局
PANSS-total score (at screening, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52)
次要结局
- [Safety] AEs (at baseline, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52)
- SAS, AIMS, Barnes (at baseline, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52)
- vital signs (at screening, baseline, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52)
- Pharmacokinetic is evaluated by concentration of aripiprazole in blood (at Week 3, 4, 6, 8).
- [Efficacy] PANSS-positive, PANSS-negative, CGI-severity score (at screening, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52)
- body weight (at screening, baseline, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52)
- electrocardiogram (ECG) (at screening & week 8)
- serum prolactin concentration (at screening & week 8)
- routine laboratory test (at screening & week 8)
- urinalysis (at screening & week 8)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
2 期
The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene MutationProstate CarcinomaMetastatic Castration-resistant Prostate CancerProstate CancerNCT05262608Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University30
招募中
不适用
IBS Titan™ Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System Clinical TrialInfrapopliteal LesionsCritical Limb IschemiaNCT05971394Biotyx Medical (Shenzhen) Co., Ltd.100
Enrolling By Invitation
2 期
the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With TrilaciclibNon-small Cell Lung CancerNCT06370416Henan Cancer Hospital41
进行中（未招募）
不适用
Clinical Investigation of the da Vinci Surgical SystemThymomaMediastinal TumorGynecologic DiseaseGynecologic CancerPelvic Organ ProlapseProstate DiseaseVentral HerniaObesity, MorbidProstate CancerInguinal HerniaNCT05682742Intuitive Surgical53
已完成
3 期
Pioglitazone Add-on Study in Patients With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00086502Merck Sharp & Dohme LLC353